A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer

Trial Profile

A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Erlotinib (Primary) ; Tivantinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 22 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top